Results 91 to 100 of about 10,088 (191)

Improving solubility and storage stability of rifaximin: Via solid-state solvation with Transcutol®

open access: yes, 2019
Crystallization of rifaximin from 2-(2-ethoxyethoxy)ethanol (Transcutol®, DEGME or DEGEE), an inactive ingredient approved by the FDA and a solvent commonly used in the pharmaceutical and cosmetic fields, affords a crystalline form of the API with better
Sforzini A.   +6 more
core   +1 more source

The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-alpha

open access: yes
Background & Aims: Rifaximin-alpha reduces the risk of recurrence of overt hepatic encephalopathy. However, there remain concerns regarding the financial cost of the drug.
Shawcross D   +16 more
core   +3 more sources

Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial

open access: yesTherapeutic Advances in Gastroenterology, 2017
Background: Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D.
Brooks D. Cash   +6 more
doaj   +1 more source

Rifaximin for the treatment of acute infectious diarrhea

open access: yes, 2011
Rifaximin is a nonabsorbable rifamycin derivative with an excellent safety profile and a broad spectrum of antimicrobial activity against a variety of enteropathogens causing acute infectious diarrhea.
Joo Sung Kim, Kyoung Sup Hong
core   +1 more source

Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4/NFκB pathway

open access: yesScientific Reports
Metabolic dysfunction-associated steatohepatitis (MASH) has become a serious public health problem, posing an increasingly dangerous threat to human health owing to its increasing prevalence and accompanying intra- and extrahepatic adverse outcomes ...
Ting Qiu   +5 more
doaj   +1 more source

Crystal forms of rifaximin and their effect on pharmaceutical properties

open access: yes, 2008
Five distinct crystal forms of rifaximin have been identified and characterised by X-ray powder diffraction, solid state 13C NMR, and HATR-IR spectroscopy.
M. Campana   +9 more
core   +1 more source

Efficacy and Safety of Short-term Administration of Rifaximin in the Treatment of Hepatic Encephalopathy [PDF]

open access: yes, 2001
Background/Aims: A prospective, randomized study was performed to evaluate the efficacy and safety of the short-term administration of rifaximin in the treatment of hepatic encephalopathy.
이관식, 백용한
core  

Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis

open access: yesBMC Gastroenterology
Background Hepatic encephalopathy (HE) is a neuropsychiatric syndrome that affects the prognosis of patients with liver disease and is considered an independent risk factor for hospitalization and death. Rifaximin has been approved for HE treatment. This
Guihua Fang, Shuna Liu, Bin Liu
doaj   +1 more source

Bears, beets, rifaximin

open access: yesCanadian Liver Journal, 2021
Peter L, Wang, Jennifer A, Flemming
openaire   +2 more sources

Home - About - Disclaimer - Privacy